Clinical Trial Update: A Phase I/II Study of Ibrutinib in Previously Treated Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II study of ibrutinib in previously treated EGFR-mutant non-small cell lung cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Ibrutinib (ibrutinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Lung Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-10-25